All In Biotech

Drug Trial Radar · NCT07765524

A Phase I/II Open-label, Single-arm, Multicenter Clinical Study to Evaluate the Safety and Efficacy of FKC289 in Subjects With Relapsed/Refractory Primary AL Amyloidosis

Last checked: Nov 19, 2026Latest source record: Aug 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

32

Planned (sponsor's estimate)

Start

Aug 2026

Primary completion

Mar 2028

Study completion Sep 2029

Sponsor

Sponsor type
Industry
First posted
Aug 14, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase I study is designed to evaluate the safety and efficacy of FKC289 in subjects with relapsed/refractory primary light chain (AL) amyloidosis.The primary objectives are to assess the safety of FKC289 and to establish the recommended Phase II dose (RP2D). And this Phase II study is designed to evaluate the efficacy of FKC289.The primary objectives are to assess proportion of subjects with hematologically best complete response (CR) within 6 months.

Conditions

  • Primary Light Chain (AL) Amyloidosis

Interventions

  • FKC289 infusionDrug

    Anti-BCMA/CD19 chimeric antigen receptor autologous T cells

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-Limiting Toxicity (DLT)Time frame: Within 28 days after FKC289 infusion
  2. Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Within 24 months after FKC289 infusion
  3. Replication Competent Lentivirus (RCL)Time frame: Within 24 months after FKC289 infusion

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • The Frist Affiliated Hospital of Jinan University

    Guangzhou, Guangdong, China

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China

  • The Frist Affiliated Hospital of Guangxi Medical university

    Nanning, Guangxi, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • Tongji Mecial college of HUST

    Wuhan, Hubei, China

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, China

  • Qilu Hospital of Shandong University

    Jinan, Shandong, China

  • Zhongshan Hospital Fudan University

    Shanghai, Shanghai Municipality, China

  • Sichuan Provincial People's Hospital

    Chengdu, Sichuan, China

  • West China Hospital Sichuan Hospital

    Chengdu, Sichuan, China

  • The Second Affiliated Hospital Zhejiang University school of Medicine

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.